Abstract：
UNASSIGNED: The 0.18 mg fluocinolone acetonide implant (FAi) is marketed for up to 36 months for treatment of noninfectious uveitis. An additional short-term corticosteroid burst prior to the 0.18 mg FAi, followed by attempt at long-term inflammation control with the 0.18 mg FAi may be beneficial given the low dose of the implant. We retrospectively reviewed all patients undergoing this treatment approach at our institution to determine its efficacy.
UNASSIGNED: Patients who received a corticosteroid burst followed by the 0.18 mg FAi with at least 6-month follow-up post 0.18 mg FAi were included. The primary outcome, treatment escalation (defined as worsening inflammation requiring escalation of therapy), was modeled using Kaplan-Meier analysis. Secondary outcomes included cystoid macular edema (CME), central macular thickness, retinal vasculitis, visual acuity, anterior chamber and vitreous cell, use of systemic therapy, use of corticosteroid drops, IOP, number of IOP lowering medications, need for glaucoma surgery, need for cataract surgery, and additional local corticosteroids.
UNASSIGNED: 32 eyes were included (mean follow-up: 19.8 months). Prior to corticosteroid burst, 37.5% were on systemic therapy, 53% had CME, and 25% had retinal vasculitis. At FAi visit, CME had decreased to 18.8%. Mean time to treatment escalation after FAi was 20.3 months (95% CI 14.8-25.7 months). No patient discontinued systemic therapy and on average 15.0% of eyes required additional local corticosteroids at each follow-up interval.
UNASSIGNED: This treatment approach demonstrates that the 0.18 mg FAi is a useful adjuvant for the treatment of noninfectious uveitis but may not be adequate as solo therapy.
UNASSIGNED: Patients who received a corticosteroid burst followed by the 0.18 mg FAi with at least 6-month follow-up post 0.18 mg FAi were included. The primary outcome, treatment escalation (defined as worsening inflammation requiring escalation of therapy), was modeled using Kaplan-Meier analysis. Secondary outcomes included cystoid macular edema (CME), central macular thickness, retinal vasculitis, visual acuity, anterior chamber and vitreous cell, use of systemic therapy, use of corticosteroid drops, IOP, number of IOP lowering medications, need for glaucoma surgery, need for cataract surgery, and additional local corticosteroids.
UNASSIGNED: 32 eyes were included (mean follow-up: 19.8 months). Prior to corticosteroid burst, 37.5% were on systemic therapy, 53% had CME, and 25% had retinal vasculitis. At FAi visit, CME had decreased to 18.8%. Mean time to treatment escalation after FAi was 20.3 months (95% CI 14.8-25.7 months). No patient discontinued systemic therapy and on average 15.0% of eyes required additional local corticosteroids at each follow-up interval.
UNASSIGNED: This treatment approach demonstrates that the 0.18 mg FAi is a useful adjuvant for the treatment of noninfectious uveitis but may not be adequate as solo therapy.
摘要：
■0.18mg醋酸氟轻松植入物（FAi）的销售时间长达36个月，用于治疗非感染性葡萄膜炎。在0.18mgFAi之前额外的短期皮质类固醇爆发，随后尝试使用0.18mgFAi进行长期炎症控制，这可能是有益的，因为植入物的剂量较低。我们回顾性回顾了在我们机构接受这种治疗方法的所有患者，以确定其疗效。
■接受皮质类固醇激素爆发后接受0.18mgFAi并在0.18mgFAi后至少6个月随访的患者被包括在内。主要结果，治疗升级（定义为炎症恶化需要治疗升级），使用Kaplan-Meier分析进行建模。次要结果包括囊样黄斑水肿（CME），黄斑中心厚度,视网膜血管炎,视敏度,前房和玻璃体细胞，使用全身治疗，使用皮质类固醇滴剂，IOP,降低IOP的药物数量，需要青光眼手术，需要白内障手术，和额外的局部皮质类固醇。
■32只眼（平均随访：19.8个月）。在皮质类固醇爆发之前，37.5％的患者接受系统治疗，53%有CME，25%患有视网膜血管炎。在FAi访问中，CME已降至18.8%。FAi后平均治疗升级时间为20.3个月(95%CI14.8-25.7个月)。没有患者停止全身治疗，平均15.0％的眼睛在每个随访间隔需要额外的局部皮质类固醇。
■这种治疗方法表明，0.18mgFAi是治疗非感染性葡萄膜炎的有用佐剂，但可能不足以作为单独治疗。
■接受皮质类固醇激素爆发后接受0.18mgFAi并在0.18mgFAi后至少6个月随访的患者被包括在内。主要结果，治疗升级（定义为炎症恶化需要治疗升级），使用Kaplan-Meier分析进行建模。次要结果包括囊样黄斑水肿（CME），黄斑中心厚度,视网膜血管炎,视敏度,前房和玻璃体细胞，使用全身治疗，使用皮质类固醇滴剂，IOP,降低IOP的药物数量，需要青光眼手术，需要白内障手术，和额外的局部皮质类固醇。
■32只眼（平均随访：19.8个月）。在皮质类固醇爆发之前，37.5％的患者接受系统治疗，53%有CME，25%患有视网膜血管炎。在FAi访问中，CME已降至18.8%。FAi后平均治疗升级时间为20.3个月(95%CI14.8-25.7个月)。没有患者停止全身治疗，平均15.0％的眼睛在每个随访间隔需要额外的局部皮质类固醇。
■这种治疗方法表明，0.18mgFAi是治疗非感染性葡萄膜炎的有用佐剂，但可能不足以作为单独治疗。
